How the biosimilars market in Europe has changed and what opportunities for biosimilars exist for the near term in the region is being reviewed by Murray Aitken in this article [1].
- INICIO
-
Genéricos
Novedades
- Five Chinese companies join UN’s MPP for Covid-19 medicines
- South Korean companies to make generic Bridion and COVID-19 drugs
- Revlimid (lenalidomide) generics launch across Europe
- Cancer and diabetes generic treatments receive positive opinion from EMA’s CHMP
Investigación
- La reutilización de medicamentos genéricos puede ahorrar tiempo y dinero
- Availability of medicines and the sustainable development of the national health system in Russia
- Generic etoricoxib is equivalent to the reference drug
- Call for drug pricing transparency
-
Biosimilares
Novedades
- Nuevos biosimilares de adalimumab se preparan para su lanzamiento en Canadá, EE.UU. y Europa
- FDA approves Amneal’s bevacizumab biosimilar
- Europe: positive opinion for Inpremzia and Truvelog Mix 30 and Stimufend authorized
- FDA approves Kashiv Biosciences’ filgrastim biosimilar
Investigación
- Totality of evidence supporting approval of Avsola in the treatment of IBD
- Innovent and Eli Lilly announce final results for sintilimab plus biosimilar bevacizumab injection
- Survey results of biosimilars use among Spanish physicians and pharmacists
- Amgen announces positive phase III results for ustekinumab biosimilar
- MORE EDITORIAL SECTIONS
- Search
Post your comment